Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related GEVA
Bernstein: Alexion Pharma An Outperform, Worth $267/Share
Synageva Reports Closing of Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopholysaccharidosis IIIB
Related
Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders
Benzinga's Top Initiations

Goldman Sachs initiated coverage on shares of Synageva BioPharma (NASDAQ: GEVA) with a “buy” rating. The target price for Synageva BioPharma is set to $72. Synageva BioPharma's shares closed at $52.61 yesterday.

Bank of America initiated coverage on shares of Prothena (NASDAQ: PRTA) with a “neutral” rating. The target price for Prothena is set to $28. Prothena's shares closed at $27.09 yesterday.

Analysts at Mizuho Securities initiated coverage on shares of Abercrombie & Fitch Company (NYSE: ANF) with a “neutral” rating. Abercrombie & Fitch's shares closed at $35.16 yesterday.

Analysts at DA Davidson initiated coverage on shares of Exterran Holdings (NYSE: EXH) with a “neutral” rating. The target price for Exterran Holdings is set to $35. Exterran's shares closed at $32.78 yesterday.

Latest Ratings for GEVA

DateFirmActionFromTo
May 2015BairdDowngradesOutperformNeutral
Mar 2015JP MorganDowngradesOverweightNeutral
Feb 2015CitigroupMaintainsNeutral

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ANF + EXH)

Around the Web, We're Loving...

Get Benzinga's Newsletters